Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck licenses Dynavax's Heplisav

DVAX granted MRK an exclusive, worldwide license to HBV vaccine Heplisav.

Read the full 118 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE